These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2521960)

  • 21. In vivo release of [3H]gamma-aminobutyric acid in the rat neostriatum--II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen.
    Girault JA; Spampinato U; Glowinski J; Besson MJ
    Neuroscience; 1986 Dec; 19(4):1109-17. PubMed ID: 2950336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.
    Oblin A; Zivkovic B; Bartholini G
    Brain Res; 1987 Sep; 421(1-2):387-90. PubMed ID: 2446703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical modification reveals involvement of tyrosine in ligand binding to dopamine D1 and D2 receptors.
    Srivastava LK; Mishra RK
    Biochem Int; 1990; 21(4):705-14. PubMed ID: 2241996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative analysis of the interaction of [3H]spiroperidol with serotonin and dopamine receptors.
    McGonigle P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S73-7. PubMed ID: 2459520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ; Norman AB; Creese I
    J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [3H]Fluphenazine binding to brain membranes: simultaneous measurement of D-1 and D-2 receptor sites.
    Morgan DG; Finch CE
    J Neurochem; 1986 May; 46(5):1623-31. PubMed ID: 2937884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol.
    Kostrzewa RM; Saleh MI
    Brain Res Dev Brain Res; 1989 Jan; 45(1):95-101. PubMed ID: 2645067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum.
    Zhang X; Segawa T
    Jpn J Pharmacol; 1989 Jul; 50(3):333-45. PubMed ID: 2569545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of prolonged treatment with neuroleptics on dopamine D-1 and D-2 receptor density in corpus striatum of mice.
    Hyttel J
    Acta Pharmacol Toxicol (Copenh); 1986 Nov; 59(5):387-91. PubMed ID: 2880451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of flunarizine with dopamine D2 and D1 receptors.
    Ambrosio C; Stefanini E
    Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors.
    Porceddu ML; Ongini E; Biggio G
    Eur J Pharmacol; 1985 Dec; 118(3):367-70. PubMed ID: 2935413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
    See RE; Aravagiri M; Ellison GD
    Life Sci; 1989; 44(3):229-36. PubMed ID: 2536879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity.
    McCabe RT; Hanson GR; Dawson TM; Wamsley JK; Gibb JW
    Neuroscience; 1987 Oct; 23(1):253-61. PubMed ID: 2891082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions.
    Memo M; Pizzi M; Nisoli E; Missale C; Carruba MO; Spano P
    Eur J Pharmacol; 1987 Jun; 138(1):45-51. PubMed ID: 2887436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390.
    Cross AJ; Mashal RD; Johnson JA; Owen F
    Neuropharmacology; 1983 Nov; 22(11):1327-9. PubMed ID: 6141534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D1 and D2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis).
    Madras BK; Fahey MA; Canfield DR; Spealman RD
    J Neurochem; 1988 Sep; 51(3):934-43. PubMed ID: 2970527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213.
    Pugh MT; O'Boyle KM; Molloy AG; Waddington JL
    Psychopharmacology (Berl); 1985; 87(3):308-12. PubMed ID: 2934758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics.
    Memo M; Battaini F; Spano PF; Trabucchi M
    Acta Psychiatr Scand; 1981 Apr; 63(4):314-24. PubMed ID: 7315480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topography of dopamine D-1 and D-2 receptor-mediated rotation after intrastriatal injections of dopamine-related drugs in normosensitive rats.
    Konitsiotis S; Kafetzopoulos E
    Eur J Pharmacol; 1990 Apr; 179(1-2):201-5. PubMed ID: 2142084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.